+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
UCB (Union chimique belge) - logo

UCB is a global biopharmaceutical company that focuses on neurology and immunology. The company’s core products are Cimzia, Vimpat, Neupro, Keppra and Briviact, and they are also preparing the launch of a potential medicine to help patients with osteoporosis. It offers products for the treatment of central nervous system disorders, allergy and respiratory diseases, and immune and inflammatory disorders. UCB employs over 7,000 people and is based in Brussels, Belgium.

GABA A Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

GABA A Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Generalized Myasthenia Gravis (gMG) - Pipeline Insight, 2025 - Product Thumbnail Image

Generalized Myasthenia Gravis (gMG) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Refractory Epilepsy - Pipeline Insight, 2025 - Product Thumbnail Image

Refractory Epilepsy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
From
Asthma Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Asthma Therapeutics - Global Strategic Business Report

  • Report
  • May 2025
  • 194 Pages
  • Global
From
cFMS Kinase Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

cFMS Kinase Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
From
From
Loading Indicator